Evidence map›Paper›PMID 25711526›Full record

ArticleMicrovascular research2015

Mechanisms of tubulogenesis and endothelial phenotype expression by MSCs.

Julie A Rytlewski, M Alejandra Aldon, Evan W Lewis, Laura J Suggs

Open access · greenAbstract read
In one paragraph

Article in Microvascular research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. State of the field: cellular and exosomal therapeutic approaches in vascular regeneration.American journal of physiology. Heart and circulatory physiology · 2022
    Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Julie A RytlewskiDepartment of Biomedical Engineering, The University of Texas at Austin, 107 W Dean Keeton, Stop C0800, Austin, TX 78712, USA. Electronic address: julie.rytlewski@utexas.edu.
M Alejandra AldonDepartment of Biomedical Engineering, The University of Texas at Austin, 107 W Dean Keeton, Stop C0800, Austin, TX 78712, USA. Electronic address: alejandra.aldon@utexas.edu.
Evan W LewisDepartment of Biomedical Engineering, The University of Texas at Austin, 107 W Dean Keeton, Stop C0800, Austin, TX 78712, USA. Electronic address: evan.lewis@utexas.edu.
Laura J SuggsDepartment of Biomedical Engineering, The University of Texas at Austin, 107 W Dean Keeton, Stop C0800, Austin, TX 78712, USA. Electronic address: laura.suggs@engr.utexas.edu.
The University of Texas at Austin · USFred Hutch Cancer Center · US

Funding

Nanotracer Development to Track Stem Cell TherapyR01EB015007 · NIBIB · UNIVERSITY OF TEXAS AT AUSTIN · PI SUGGS, LAURA J · 2012 to 2020
$3.7M
Multiphoton Microscope for Biomedical Engineering ApplicationsS10RR027950 · NCRR · UNIVERSITY OF TEXAS AT AUSTIN · PI TUNNELL, JAMES W · 2011 to 2011
$600k
NCRR NIH HHS S10 RR027950NCRR NIH HHS S10RR027950NIBIB NIH HHS R01 EB015007
6 · The paper itself

Abstract

Stem cell-based therapies are a promising new avenue for treating ischemic disease and chronic wounds. Mesenchymal stem cells (MSCs) have a proven ability to augment the neovascularization processes necessary for wound healing and are widely popular as an autologous source of progenitor cells. Our lab has previously reported on PEGylated fibrin as a unique hydrogel that promotes spontaneous tubulogenesis of encapsulated MSCs without exogenous factors. However, the mechanisms underlying this process have remained unknown. To better understand the therapeutic value of PEGylated fibrin delivery of MSCs, we sought to clarify the relationship between biomaterial properties and cell behavior. Here we find that fibrin PEGylation does not dramatically alter the macroscopic mechanical properties of the fibrin-based matrix (less than 10% difference). It does, however, dramatically reduce the rate of diffusion through the gel matrix. PEGylated fibrin enhances the tubulogenic growth of encapsulated MSCs demonstrating fluid-filled lumens by interconnected MSCs. Image analysis gave a value of 4320 ± 1770 μm total network length versus 618 ± 443 μm for unmodified fibrin. PEGylation promotes the endothelial phenotype of encapsulated MSCs--compared to unmodified fibrin--as evidenced by higher levels of endothelial markers (von Willebrand factor, 2.2-fold; vascular endothelial cadherin, 1.8-fold) and vascular endothelial growth factor (VEGF, up to 1.8-fold). Prospective analysis of underlying molecular pathways demonstrated that this endothelial-like MSC behavior is sensitively modulated by hypoxic stress, but not VEGF supplementation as evidenced by a significant increase in VEGF and MMP-2 secretion per cell under hypoxia. Further gain-of-function studies under hypoxic stress demonstrated that hypoxia culture of MSCs in unmodified fibrin could increase both vWF and VE-cadherin levels to values that were not significantly different than cells cultured in PEGylated fibrin. This result corroborated our hypothesis that the diffusion-limited environment of PEGylated fibrin is augmenting endothelial differentiation cues provided by unmodified fibrin. However, MSC networks lack platelet endothelial cell adhesion molecule-1 (PECAM-1) expression, which indicates incomplete differentiation towards an endothelial cell type. Collectively, the data here supports a revised understanding of MSC-derived neovascularization that contextualizes their behavior and utility as a hybrid endothelial-stromal cell type, with mixed characteristics of both populations.

Indexed as

Antigens, CDBone Marrow CellsCadherin 5CadherinsCell DifferentiationCell HypoxiaCell ProliferationDiffusionEndothelium, VascularFibrinFluorescent DyesGene Expression RegulationHumansMesenchymal Stem CellsMicroscopy, Electron, ScanningMicroscopy, Phase-ContrastAntigens, CDCadherin 5CadherinsFibrinFluorescent DyesPlatelet Endothelial Cell Adhesion Molecule-1Polyethylene GlycolsVascular Endothelial Growth Factor AVEGFA protein, humanvon Willebrand FactorFibrinHypoxiaMesenchymal stem cellsNeovascularizationTubulogenesisVasculogenic mimicry

Identifiers

PMID25711526
PMCPMC4426083
OpenAlexW2032654682

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.